David Stein, MD
Psychiatry · Honolulu, HINPI 1740386341
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,463 of the $186,088 with a category attached, or 72.8%. 22 manufacturers reported payments, led by AbbVie at 36.4% of the total. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,425 payments — averaging $130.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Alkermes, Inc.$67K
- Otsuka America Pharmaceutical, Inc.$15K
- E.r. Squibb & Sons, L.L.C.$15K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Sunovion Pharmaceuticals Inc.$3K
- plus $14K from 16 others
What the payments were for
- Consulting fees$2700%
- Speaking & faculty fees$135,46373%
- Travel & lodging$16,8569%
- Food & beverage$33,49918%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 233 | $67,767 |
| Alkermes, Inc. | 207 | $66,801 |
| Otsuka America Pharmaceutical, Inc. | 62 | $15,110 |
| E.r. Squibb & Sons, L.L.C. | 44 | $14,830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 192 | $3,915 |
| Sunovion Pharmaceuticals Inc. | 171 | $3,251 |
| Neurocrine Biosciences, Inc. | 77 | $3,243 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 133 | $3,173 |
| Teva Pharmaceuticals USA, Inc. | 103 | $2,713 |
| Johnson & Johnson | 53 | $1,500 |
| Lundbeck LLC | 70 | $993 |
| Axsome Therapeutics, Inc. | 16 | $752 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $443 |
| Vanda Pharmaceuticals Inc. | 19 | $416 |
| Janssen Scientific Affairs, LLC | 3 | $330 |
| Eisai Inc. | 7 | $224 |
| Idorsia Pharmaceuticals US Inc | 4 | $189 |
| Corium, LLC | 13 | $184 |
| Merck | 7 | $121 |
| Indivior Inc. | 4 | $93 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$251,754
- VRAYLAR$64,327
- REXULTI$14,045
- COBENFY$13,722
- INGREZZA$2,303
- ARISTADA$1,908
- TRINTELLIX$1,800
- CAPLYTA$1,468
- INVEGA SUSTENNA$919
- AUSTEDO$640
- ARISTADA INITIO$477
- Auvelity$462
- SPRAVATO$375
- INVEGA TRINZA$373
- LATUDA$358
- Austedo XR$243
- UZEDY$235
- ABILIFY MAINTENA$233
- QUVIVIQ$125
- Dayvigo$125
How this compares
$186,088 in reported general payments places this provider in the 95th percentile of 183 psychiatry providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 13 | $119,866 |
| AristadaAripiprazole Lauroxil | 23 | $73,752 |
| VraylarCariprazine Hcl | 35 | $67,331 |
| CaplytaLumateperone Tosylate | 28 | $49,012 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $43,295 |
| Invega SustennaPaliperidone Palmitate | 22 | $39,868 |
| TrintellixVortioxetine Hydrobromide | 41 | $31,018 |
| RexultiBrexpiprazole | 13 | $20,511 |
| LexaproEscitalopram Oxalate | 12 | $10,670 |
| Paliperidone ErPaliperidone | 44 | $6,549 |
| Bupropion XlBupropion Hcl | 159 | $5,868 |
| Lisdexamfetamine Dimesylate | 13 | $3,642 |
| Aripiprazole | 42 | $3,226 |
| Asenapine Maleate | 16 | $3,209 |
| Buspirone Hcl | 98 | $2,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,500 | $159,73435 claims |
| Alkermes, Inc.Aristada, Lybalvi | $66,801 | $117,04649 claims |
| AbbVieVraylar, Lexapro | $67,767 | $78,00247 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,173 | $49,01228 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,915 | $31,01841 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15,110 | $20,51113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 psychiatry providers in Hawaii.
Other psychiatry in Honolulu
- Denis Mee-LeeHonolulu$526K
- Gregory YuenHonolulu$6K
- Raymond DavidsonHonolulu$6K
- Helen Blaisdell-BrennanHonolulu$6K
- Glorifin BelmonteHonolulu$5K
- Brett LuHonolulu$5K
- Donna McBrien SliwowskiHonolulu$4K
- Alan BuffensteinHonolulu$3K
- Nancy LuckieHonolulu$3K
- Angela KingHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.